IGF-1 DES is the most potent naturally occurring form of IGF-1, created by removal of the first three amino acids. This small modification eliminates most binding protein interactions, freeing the peptide to act immediately and powerfully at IGF-1 receptors — but only briefly.
Research Applications
Local tissue growth signaling, site-specific muscle research, wound healing, and IGF-1 receptor pharmacology studies.
Dosage Information (Research Use)
Research protocols: 50-150 mcg injected locally into target tissue, pre- or post-training. Very short window of activity. Research use only.
Reconstitution & Handling
Reconstitute with BAC water or 0.6% acetic acid. Use promptly — less stable than LR3 variant.
Half-Life & Pharmacokinetics
Approximately 20-30 minutes. Ultrashort — designed for local, immediate action.
Reported Observations in Literature
Hypoglycemia risk (potent insulin-like activity). Local injection site reactions. Systemic effects minimal due to short half-life.
Key Research References
- Francis GL, et al. “Novel recombinant fusion protein analogues of insulin-like growth factor (IGF)-I indicate the relative importance of IGF-binding protein and receptor binding.” J Mol Endocrinol. 1992